-
Mashup Score: 0Jennifer Johnston (@jennifer.b.johnston) • Instagram photo - 9 month(s) ago
21 likes, 1 comments – jennifer.b.johnston on August 17, 2023: “Two years ago I was estatic that Dr. Wang answered my email from Alaska. I felt once I was accep…”
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Special Issue "Cutaneous Lymphomas" - PubMed - 1 year(s) ago
Cutaneous lymphomas comprise heterogeneous subtypes of hematological neoplasms that primarily manifest in the skin […].
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Lymphoma_Papers: Special Issue "Cutaneous Lymphomas" #lymphoma #lymsm https://t.co/My1FpQEI4B
-
-
Mashup Score: 1Resilience Is About How You Recharge, Not How You Endure - 1 year(s) ago
After working hard for long hours and toughing it out, we at least expect success. However, more often than not, at the end of the day we are exhausted and still have a long list of tasks to complete. Why does this happen? According to the authors, working adults have a fundamental misunderstanding of what it means to be resilient. Yes, resilience involves working hard, but it also requires one…
Source: Harvard Business ReviewCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrAnasYounes: Resilience Is About How You Recharge, Not How You Endure https://t.co/QfJjG3GkqC
-
-
Mashup Score: 2Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL - 1 year(s) ago
Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Umich20221: Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL https://t.co/Ig6FwLmwyw via @onclive
-
-
Mashup Score: 0Dan Seals & Marie Osmond ~ Meet Me In Montana - 1 year(s) ago
I love country music. Guess youalready knew that by my channelname. Yep. 🙂 Is nice in full screen and hd. :)Rest in peace Dan Seals…Lyrics:Wrote my whole …
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Dan Seals & Marie Osmond ~ Meet Me In Montana https://t.co/FjP2e3Rg7C via @YouTube ‘Why won’t you meet me in Montana, I want to see the mountains in your eyes’! I miss Dan Seals. He was a good friend of mine.
-
-
Mashup Score: 1
Joshua Brody, MD, discussed significant updates in MCL treatment presented at the 2022 ASH Annual Meeting, including results from the phase 1/2 BRUIN trial of pirtobrutinib, follow-up data from the phase 2 ZUMA-7 trial on CAR T-cell therapies, and next steps to expand the development of immunotherapies in this disease.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Umich20221: Advancements in Immunotherapy Expand and Improve the Treatment Landscape for MCL https://t.co/34GfP6rsrT via @onclive
-
-
Mashup Score: 1NCI Outstanding Investigator Award Recipients - 2 year(s) ago
Learn how these investigators’ projects aim to break new ground in biomedical, behavioral, and clinical cancer research.
Source: National Cancer InstituteCategories: Hem/Oncs, Latest HeadlinesTweet-
With my profound admiration!NCI Outstanding Investigator Award Recipients - NCI https://t.co/BgWXeX4xyU
-
-
Mashup Score: 0Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities - PubMed - 2 year(s) ago
Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last two decades following the introduction of highly active immunotherapies, such as rituximab. Since then, the field has continued to witness tremendous progress with the introduction of newer, more poten …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities - PubMed https://t.co/3hpFiX0aqt
-
-
Mashup Score: 1Predicting the future in MCL with MRD - 2 year(s) ago
In this issue of Blood, Ferrero et al1 present a comprehensive, longitudinal analysis of molecular measurable residual disease (MRD) assessments in patients wit
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Predicting the future in MCL with MRD | Blood | American Society of Hematology https://t.co/9rhmFTYL3h
-
-
Mashup Score: 1Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer - 2 year(s) ago
The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in the treatment of various malignancies. Despite CAR-T cell therapy…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Martin_AngelMD: CAR-T cell therapy in solid tumors.... Coming soon! #IO @OncoAlert https://t.co/pHlkwtgdYt
-
Jennifer, we are so proud of you! @jennifer.b.johnston https://t.co/DstNTmIS18